(Adnkronos) - ‘Partner per il futuro’. Così che Novartis guarda alle associazioni pazienti: alleati con cui collaborare e dialogare per costruire e re-immaginare la salute. Proprio per questo, nel 2023, la farmaceutica ha dato vita, con la collaborazione di numerosi attori del sistema, alla piattaforma all’interno della quale si inserisce l’evento ‘Insieme alle associazioni pazienti per re-immaginare l’accesso all’innovazione’, primo di un ciclo di tre incontri che si è svolto a Milano.
Category
🗞
NewsTranscript
00:00Collaboration, future, dialogue and health, these are the key words from which Partner for the future is born, the platform created in 2023 by Novartis and in the field of which the first of three meetings focused on the importance of collaboration with the Association of Patients to reimagine together the future. At the center of the first meeting, accessibility, innovation.
00:27The mission of Novartis Italy is to reimagine medicine, but we cannot think of reimagining medicine without listening to those who live the pathology first, that is, the patients.
00:40We have learned as a company to listen to them, to co-create with them and we have discovered a huge value that we have implemented in a systemic way in our processes.
00:51And this is the reason why we believe that the system, today's health, must include the patient's point of view, because equally, or perhaps even more, it will be the value of listening to them, of co-creating with them and of including their point of view in the decision-making processes.
01:11To ensure the national level, patients, associations, participation, decision-making tables, the latest balance sheet.
01:19Patient associations can say that from January 2025 they have made a real step forward, because the institutions have realized our importance and have officially put in the balance sheet our participation in the tables where decisions are made. So I would say that we are very satisfied.
01:42The European Union has also taken action to enhance the contribution of patient associations with the Health Technology Assessment.
01:50Basically, there is a joint clinical assessment of some therapies, specifically of oncological products and advanced therapies, as a pilot this year at the European level, and an assessment of non-clinical domains at the national level, therefore belonging to the Member States.
02:15There must therefore be a strong collaboration between the world of institutions, the world of developers, scientific societies and patient associations, so that the value of a health technology can somehow be put to the ground according to the logic of the HTA.
02:34The logic of the HTA provides nine different perspectives that essentially evaluate a new technology, and one of the perspectives concerns precisely the perspective of the patient association.